Veteran pharmaceutical leader Don DeGolyer, former CEO of Sandoz Inc., has co-founded Ategenos, a PharmaTech startup preparing for its public launch. The company aims to tackle the global crisis of medication non-adherence, a problem costing $1 trillion worldwide.

Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against RxSight, Inc., claiming that top executives made false and misleading statements in violation of federal securities laws. Investors who suffered substantial losses are encouraged to join the lawsuit before the September 22, 2025 deadline.

Xeltis has announced positive preliminary data from its ongoing EU clinical trial of the Xabg coronary artery bypass conduit. The study evaluates the technology in patients with multi-vessel coronary artery disease scheduled for elective bypass surgery.

Merck’s stock encounters significant hurdles as it approaches the Keytruda patent cliff and grapples with challenges related to Gardasil. A recent SWOT analysis reveals potential vulnerabilities that could impact the pharmaceutical giant’s financial outlook.

New research uncovers how prophages prevent superinfection by blocking bacterial cell surface receptors, ensuring the survival of their viral progeny.

In a groundbreaking move, the MLB All-Star Game introduced “robot umpires,” offering fans a firsthand look at the future of baseball officiating. The integration of this technology marks a significant step in how the game may be played and judged in years to come.

Swedish biopharmaceutical company Sobi has announced a strong second quarter for 2025, with total revenue increasing by 13%. The growth is propelled by significant gains in both its haematology and immunology portfolios. Despite incurring restructuring costs, the company achieved an improved adjusted EBITA margin, reflecting enhanced operational efficiency.

HSBC analysts are expressing skepticism about the profitability of robotaxis, cautioning that hidden costs could delay returns for years. Despite the rapid development by companies like Tesla and Waymo, the market for driverless taxis may be widely overestimated.

Researchers have discovered a novel way to retrain neutrophils—the body’s first responders—to directly attack aggressive breast cancer cells, offering new hope to patients unresponsive to current immunotherapies.

A self-driving lab is turning the tide in material discovery, collecting data ten times faster and paving the way for rapid scientific breakthroughs.

Just a week before groundbreaking HIV vaccine trials were set to begin, South African scientists received an email halting their efforts—aid cuts had struck a devastating blow to critical research.

The chair of Solvonis is set to participate in a biotech leadership panel, highlighting the company’s involvement in industry advancements.

Tesla is set to face its first jury trial over its autopilot system in a Miami federal court on Monday, a case that could significantly impact the company’s self-driving technology and reputation.

As one of 95 publicly-traded companies in the Medical Services industry, Bausch + Lomb faces a competitive landscape. This analysis examines how the company compares to its peers based on key financial metrics, including institutional ownership, profitability, earnings, risk, dividends, valuation, and analyst recommendations.

Houston Pest Management has launched a groundbreaking eco-friendly pest control system that promises rapid elimination of infestations within days. Combining biological agents with advanced digital monitoring, this innovation offers a safer alternative to traditional chemical treatments, addressing environmental and health concerns.

Filmmaker Peter Jackson is turning his passion for New Zealand’s natural history into action by partnering with biotech experts to attempt the revival of the extinct moa bird. His unique collaboration aims to bring back the flightless giant that once roamed his homeland.

Quest Diagnostics is set to offer an FDA-cleared blood test for Alzheimer’s disease developed by Fujirebio. Building on its pioneering AD-Detect™ product line, the test will be available for clinical and research use as soon as this summer, marking a significant advancement in assessing symptomatic patients.

While household names dominate the tech sector, some under-the-radar companies offer tremendous growth potential. Discover ten tech stocks that could be magnificent investments despite not being in the spotlight.

RxSight Inc. witnessed a dramatic 34% drop in after-hours trading after announcing revisions to its 2025 revenue forecast, sparking concerns among investors. The company’s stock closed at $8.40, down from $12.79, highlighting the market’s reaction to the updated financial outlook.

In a groundbreaking preclinical study, NurExone Biologic Inc.’s ExoPTEN treatment enabled 100% of animals in the high-dose group to regain motor function after spinal cord injury. The dose-dependent study offers renewed hope for future therapies, with significant improvements confirmed using advanced gait analysis technology.

In a landmark move, the Chan Zuckerberg Initiative and the Innovative Genomics Institute have announced a new center dedicated to bringing personalized CRISPR cures to children with rare genetic diseases.